The UK-based Diurnal Group was founded in 2004 and develops hormone therapeutics for the global market, focusing on rare and chronic endocrine diseases such as congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. The company's expertise lies in circadian-based endocrinology, and it uses advanced proprietary formulations and novel physiological treatment regimes of approved drugs to create its high-value therapeutics. Diurnal has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology. Its mission is to address crucial unmet patient and clinical needs in the endocrine field and deliver the best health outcomes to improve patients' quality of life.